These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrier. Critchley BJ; Gaspar HB; Benedetti S Mol Ther; 2023 Mar; 31(3):657-675. PubMed ID: 36457248 [TBL] [Abstract][Full Text] [Related]
25. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Desnick RJ; Schuchman EH Annu Rev Genomics Hum Genet; 2012; 13():307-35. PubMed ID: 22970722 [TBL] [Abstract][Full Text] [Related]
26. Emerging therapies for neuropathic lysosomal storage disorders. Kelly JM; Bradbury A; Martin DR; Byrne ME Prog Neurobiol; 2017 May; 152():166-180. PubMed ID: 27725193 [TBL] [Abstract][Full Text] [Related]
27. Treatment strategies for lysosomal storage disorders. Beck M Dev Med Child Neurol; 2018 Jan; 60(1):13-18. PubMed ID: 29090451 [TBL] [Abstract][Full Text] [Related]
28. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective. Thomas R; Kermode AR Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228 [TBL] [Abstract][Full Text] [Related]
29. Advances in therapies for neurological lysosomal storage disorders. Ellison S; Parker H; Bigger B J Inherit Metab Dis; 2023 Sep; 46(5):874-905. PubMed ID: 37078180 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification. Keyzor I; Shohet S; Castelli J; Sitaraman S; Veleva-Rotse B; Weimer JM; Fox B; Willer T; Tuske S; Crathorne L; Belzar KJ Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627292 [TBL] [Abstract][Full Text] [Related]
31. Lysosomal storage diseases: Stem cell-based cell- and gene-therapy. Kim SU Cell Transplant; 2014 May; ():. PubMed ID: 24853878 [TBL] [Abstract][Full Text] [Related]
33. Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications. Biffi A Mol Ther; 2017 May; 25(5):1155-1162. PubMed ID: 28389320 [TBL] [Abstract][Full Text] [Related]
34. Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I. Penati R; Fumagalli F; Calbi V; Bernardo ME; Aiuti A J Inherit Metab Dis; 2017 Jul; 40(4):543-554. PubMed ID: 28560469 [TBL] [Abstract][Full Text] [Related]
35. New strategies for enzyme replacement therapy for lysosomal storage diseases. Grubb JH; Vogler C; Sly WS Rejuvenation Res; 2010; 13(2-3):229-36. PubMed ID: 20345279 [TBL] [Abstract][Full Text] [Related]
36. Current state of the management of LSDs. Germain DP; Aggio M Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S61-2. PubMed ID: 20040313 [No Abstract] [Full Text] [Related]
37. Low-dose Gene Therapy Reduces the Frequency of Enzyme Replacement Therapy in a Mouse Model of Lysosomal Storage Disease. Alliegro M; Ferla R; Nusco E; De Leonibus C; Settembre C; Auricchio A Mol Ther; 2016 Dec; 24(12):2054-2063. PubMed ID: 27658524 [TBL] [Abstract][Full Text] [Related]
38. Perspectives from B cell immunology: fact and fancy. Hunt SV Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S86-99. PubMed ID: 20040318 [TBL] [Abstract][Full Text] [Related]
39. Novel therapies and future perspectives. Scarpa M; Frustaci A Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S109-10. PubMed ID: 20040320 [No Abstract] [Full Text] [Related]
40. Genetics and Gene Therapy of Anderson-Fabry Disease. Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]